Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 16, Issue 11, Pages 1767-1773Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.41105
Keywords
B7-H3; CD276; cancer immunotherapy; antibody; immune checkpoint
Categories
Funding
- Science and Technology Development Fund, Macau SAR [FDCT/131/2016/A3, FDCT/0015/2018/A1]
- National Key R&D Program of China [2019YFA0904400]
- Guangzhou Science and Technology Program [201807010004]
- Faculty of Health Sciences, University of Macau
- [MYRG2019-00069-FHS]
- [SRG2016-00082-FHS]
Ask authors/readers for more resources
B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may be a promising target for cancer treatment. B7-H3 protein was demonstrated to be expressed in several kinds of tumor tissues including non-small-cell lung cancer (NSCLC) and prostate cancer. Its expression is highly associated with undesirable treatment outcomes and survival time, due to function of the immune checkpoint molecule. It was classified as either a co-stimulatory molecule for T cell activation or the nonimmunological role of regulating signaling pathways. Although there is still no agreed conclusion on the function of B7-H3, it may be a valuable target for cancer therapy. This review aims to provide a comprehensive, up-to-date summary of the advances in B7-H3 targeting approaches in cancer therapy. Although several challenges remain, B7-H3 offers a new therapeutic target with increased efficacy and less toxicity in future cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available